99% Purity Aprepitant Pharmaceutical Aprepitant Intermediate Powder Aprepitant

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Aprepitant
• Product Name: Aprepitant
• Name: Aprepitant Powder
• Appearance: White or off-White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 170729-80-3
• Mf: C23h21f7n4o3
• MW: 534.426662
• Density: 1.51
• Melting Point: 244-246 C
• Refractive Index: 1.564
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 1 Ton/Month

Product Description

99% Purity Aprepitant Pharmaceutical Aprepitant Intermediate Powder Aprepitant

 

Product Description

Product Details

Product Name	Aprepitant
CAS No.	170729-80-3
MF	C23H21F7N4O3
MW	534.426662
Appearance and shape	White or off-white crystalline powder

Aprepitant is a neurokinin-1 (NK-1) receptor antagonist, belonging to anti-cancer chemotherapeutic vomiting drugs.  This product has a highly selective affinity for humans, but has a low affinity for 5-hydroxytryptamine, dopamine and corticosteroid receptors.  Aprepitant in combination with 5-HT3 receptor inhibitors (e.g., ondansetron hydrochloride) may further reduce acute and/or delayed cisplatin induced vomiting.  Single use of this drug has a certain preventive effect.

Application & Function

Aprepitant is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists.   Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.   Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.   Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).

Specification